Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Meissner

Showing results (321-330 of 436) with videos related to

Pageof 44
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 4, 2012
Assessment of quality of life with the multiple system atrophy health-related quality of life scaleWassilios G Meissner, Alexandra Foubert-Samier, Sandrine Dupouy, et al.
Revue Neurologique|June 12, 2012
Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL)W G Meissner, A Foubert-Samier, S Dupouy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2026
The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?Nesrine Kouki, Anne Pavy-Le Traon, Viorica Chelban, et al.
The Lancet. Neurology|June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsBenjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
The Journal of Antimicrobial Chemotherapy|May 15, 2015
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirinJoseph E Rower, Eric G Meissner, Leah C Jimmerson, et al.
Bioorganic & Medicinal Chemistry Letters|October 30, 2007
Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonistsRobert J Watson, Daniel R Allen, Helen L Birch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 27, 2017
IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN SignalingAdeola A Obajemu, Nina Rao, Kari A Dilley, et al.
Movement Disorders Clinical Practice|October 17, 2022
Patient-Reported Symptoms in the Global Multiple System Atrophy RegistryJose-Alberto Palma, Florian Krismer, Wassilios G Meissner, et al.
Brain : a Journal of Neurology|July 14, 2022
Extracellular vesicle biomarkers for cognitive impairment in Parkinson's diseaseJoseph Blommer, Toni Pitcher, Maja Mustapic, et al.
Parkinsonism & Related Disorders|January 13, 2012
Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over timeNathalie Damon-Perrière, Alexandra Foubert-Samier, Valérie Cochen De Cock, et al.
Pageof 44

Showing results (321-330 of 436) with videos related to

Sort By:
Pageof 44
Movement Disorders : Official Journal of the Movement Disorder Society|October 4, 2012
Assessment of quality of life with the multiple system atrophy health-related quality of life scaleWassilios G Meissner, Alexandra Foubert-Samier, Sandrine Dupouy, et al.
Revue Neurologique|June 12, 2012
Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL)W G Meissner, A Foubert-Samier, S Dupouy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2026
The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?Nesrine Kouki, Anne Pavy-Le Traon, Viorica Chelban, et al.
The Lancet. Neurology|June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsBenjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
The Journal of Antimicrobial Chemotherapy|May 15, 2015
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirinJoseph E Rower, Eric G Meissner, Leah C Jimmerson, et al.
Bioorganic & Medicinal Chemistry Letters|October 30, 2007
Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonistsRobert J Watson, Daniel R Allen, Helen L Birch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 27, 2017
IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN SignalingAdeola A Obajemu, Nina Rao, Kari A Dilley, et al.
Movement Disorders Clinical Practice|October 17, 2022
Patient-Reported Symptoms in the Global Multiple System Atrophy RegistryJose-Alberto Palma, Florian Krismer, Wassilios G Meissner, et al.
Brain : a Journal of Neurology|July 14, 2022
Extracellular vesicle biomarkers for cognitive impairment in Parkinson's diseaseJoseph Blommer, Toni Pitcher, Maja Mustapic, et al.
Parkinsonism & Related Disorders|January 13, 2012
Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over timeNathalie Damon-Perrière, Alexandra Foubert-Samier, Valérie Cochen De Cock, et al.
Pageof 44